DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft: 33rd Ordinary Annual General Meeting of RHÖN-KLINIKUM AG
DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): AGM/EGM/AGM/EGM
RHÖN-KLINIKUM Aktiengesellschaft: 33rd Ordinary Annual General Meeting of RHÖN-KLINIKUM AG
09.06.2021 / 15:12
The issuer is solely responsible for the content of this announcement.
Corporate News
Bad Neustadt / Saale | 9th June 2021
33rd Ordinary Annual General Meeting of RHÖN-KLINIKUM AG
- Annual General Meeting resolves to carry forward the net distributable profit
- Formal approval of actions by Members of the Board of Management and Supervisory Board
- Marco Walker elected to the Supervisory Board
- Approval of remuneration system for the Board of Management
At today's Annual General Meeting (AGM) of RHÖN-KLINIKUM AG the shareholders approved the proposal by the Board of Management and Supervisory Board not to distribute a dividend for the past financial year 2020. Due to the ongoing uncertainties with regard to the further effects of the COVID 19 pandemic on the earnings and liquidity situation, the Board of Management and Supervisory Board had proposed to the AGM to carry forward the full net distributable profit of approx. Euro 193.2 million. Retaining the net distributable profit will strengthen the capital and liquidity base and safeguard the capability of RHÖN-KLINIKUM AG to make investments.
Apart from the resolution on the appropriation of the net distributable profit and the election of a Supervisory Board member, the agenda also included resolutions on the formal approval of the actions of the Board of Management and Supervisory Board for financial year 2020 and on the new remuneration system for the Board of Management. The shareholders approved all the items on the agenda. The actions of the Board of Management and Supervisory Board for financial year 2020 were approved by a clear majority.
Appeal for a National Policy to Safeguard Acceptable Medical Care
In addition to commenting on the development of financial year 2020 and the first quarter of 2021, on which RHÖN-KLINIKUM AG has already reported in detail (see Corporate News of 25th March 2021 and 6th May 2021), the Board of Management now reported on the required reforms in the German healthcare system.
The Board of Management of RHÖN-KLINIKUM AG has repeatedly articulated its requests in many discussions with national and federal state politicians. Such requests include lessening the bureaucracy in required documentation and also reducing the overall amount of documentation, the adequate financing of investments, binding planning certainty and full compensation of lost earnings for 2021, including all types of revenues and expenses, as well as overhauling the German hospital landscape pursuant to structured and transparent criteria.
"We have been heard, now it is up to the politicians to set the necessary reforms in motion. But unfortunately political mills grind very slowly and it is also necessary to correct the failures of past decades," Dr. Christian Höftberger, CEO of RHÖN-KLINIKUM AG, stated.
Marco Walker Elected to Supervisory Board
Marco Walker, 45, COO of Asklepios Kliniken GmbH & Co. KGaA, Hamburg, and Managing Director of Asklepios Kliniken Management GmbH, was elected to the Supervisory Board of RHÖN-KLINIKUM AG. He succeeds Prof. Dr. Gerhard Ehninger who resigned his mandate and left the Company's Supervisory Board on 15th January 2021. Walker was appointed as a member of the Company's Supervisory Board by order of the Amtsgericht (local court) in Schweinfurt on 3rd March 2021. Today the shareholders elected him to the board as a shareholder representative.
New Remuneration System for Board of Management
Furthermore the AGM approved a new remuneration system for the Board of Management which was developed by the Supervisory Board and adopted in March 2021. The remuneration system for the Board of Management will apply from 1st April 2021. RHÖN-KLINIKUM AG is thus putting into practice the amended regulatory requirements on Board of Management remuneration in line with the Act Implementing the Second Shareholders' Rights Directive (Gesetz zur Umsetzung der zweiten Aktionärsrechterichtlinie - ARUG II). The remuneration system is an incentive for effective and sustainable corporate management. It specifies a maximum level of remuneration and contains detailed provisions for both fixed and variable remuneration elements.
You can find the voting results and the CEO report for today's AGM under www.rhoen-klinikum-ag.com/agm.
The 2020 Annual Report is available at www.rhoen-klinikum-ag.com/annualreport.
RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. Its hospitals offer excellent medical care with a direct link to universities and research institutes. Approx. 809,000 patients are treated every year at the five group hospitals located in Bad Neustadt, Frankfurt (Oder), Giessen and Marburg as well as Bad Berka where roughly 18,450 employees work. The innovative RHÖN campus concept for offering forward-looking healthcare across sectoral boundaries in rural areas as well as consistently extending our gradual corporate digitalisation and the strategic partnership with Asklepios are key pillars of the corporate strategy. RHÖN-KLINIKUM AG is an independent company under the roof of Asklepios Kliniken GmbH & C. KGaA. www.rhoen-klinikum-ag.com
Follow us: www.twitter.com/rhoenklinikumag www.xing.com/companies/rhön-klinikumag www.youtube.com/rhönklinikumag
Contact Person:
RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
Julian Schmitt
Telephone: +49 9771 65-12250 | E-Mail: [email protected]
09.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
RHÖN-KLINIKUM Aktiengesellschaft |
|
Salzburger Leite 1 |
|
97616 Bad Neustadt a.d.Saale |
|
Germany |
Phone: |
+49 (0)9771 - 65-0 |
Fax: |
+49 (0)9771 - 97 467 |
E-mail: |
[email protected] |
Internet: |
www.rhoen-klinikum-ag.com |
ISIN: |
DE0007042301 |
WKN: |
704230 |
Listed: |
Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: |
1206193 |
|
End of News |
DGAP News Service |
1206193 09.06.2021
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
1.211,08 |
1.232,91 |
1.303,90 |
1.360,16 |
1.402,01 |
1.446,09 |
1.463,98 |
EBITDA1,2 |
97,82 |
125,54 |
125,33 |
80,23 |
101,16 |
105,65 |
105,88 |
EBITDA-Marge3 |
8,08 |
10,18 |
9,61 |
5,90 |
7,22 |
7,31 |
|
EBIT1,4 |
38,70 |
64,94 |
56,80 |
10,60 |
30,52 |
36,11 |
40,40 |
EBIT-Marge5 |
3,20 |
5,27 |
4,36 |
0,78 |
2,18 |
2,50 |
2,76 |
Jahresüberschuss1 |
36,74 |
51,19 |
44,48 |
2,46 |
30,23 |
26,94 |
40,17 |
Netto-Marge6 |
3,03 |
4,15 |
3,41 |
0,18 |
2,16 |
1,86 |
2,74 |
Cashflow1,7 |
80,30 |
49,50 |
47,30 |
113,30 |
97,50 |
41,30 |
109,00 |
Ergebnis je Aktie8 |
0,53 |
0,73 |
0,65 |
0,02 |
0,42 |
0,38 |
0,58 |
Dividende8 |
0,22 |
0,29 |
0,00 |
0,00 |
0,00 |
0,15 |
0,35 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: KPMG
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Rhön-Klinikum |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
704230 |
12,600 |
Halten |
843,73 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
21,00 |
28,42 |
0,73 |
21,54 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,67 |
7,74 |
0,58 |
7,38 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,15 |
0,00 |
0,00 |
05.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
08.05.2024 |
08.08.2024 |
07.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
2,05% |
5,27% |
26,00% |
9,57% |
|
|